GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palisade Bio Inc (NAS:PALI) » Definitions » Price-to-Owner-Earnings

Palisade Bio (Palisade Bio) Price-to-Owner-Earnings : (As of Jun. 18, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Palisade Bio Price-to-Owner-Earnings?

As of today (2024-06-18), Palisade Bio's share price is $4.6099. Palisade Bio does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Palisade Bio's Price-to-Owner-Earnings or its related term are showing as below:


PALI's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.74
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-18), Palisade Bio's share price is $4.6099. Palisade Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-23.64. Therefore, Palisade Bio's PE Ratio for today is At Loss.

As of today (2024-06-18), Palisade Bio's share price is $4.6099. Palisade Bio's EPS without NRI for the trailing twelve months (TTM) ended in was $-23.12. Therefore, Palisade Bio's PE Ratio without NRI for today is At Loss.

During the past 4 years, Palisade Bio's highest PE Ratio without NRI was 4.57. The lowest was 0.00. And the median was 0.00.


Palisade Bio Price-to-Owner-Earnings Historical Data

The historical data trend for Palisade Bio's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palisade Bio Price-to-Owner-Earnings Chart

Palisade Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - -

Palisade Bio Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Palisade Bio's Price-to-Owner-Earnings

For the Biotechnology subindustry, Palisade Bio's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Palisade Bio's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Palisade Bio's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Palisade Bio's Price-to-Owner-Earnings falls into.



Palisade Bio Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Palisade Bio's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=4.6099/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Palisade Bio  (NAS:PALI) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Palisade Bio Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Palisade Bio's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Palisade Bio (Palisade Bio) Business Description

Traded in Other Exchanges
Address
5800 Armada Drive, Suite 2A, Carlsbad, CA, USA, 92008
Palisade Bio Inc is a clinical-stage biopharma company. It is advancing oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio's innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery.
Executives
Donald Allen Williams director C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
John David Finley officer: Chief Financial Officer C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Robert J. Trenschel director C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Mitchell Lawrence Jones officer: Chief Medical Officer 70 GALLOUPES POINT ROAD, SWAMPSCOTT MA 01907
Robert Curtis Mcrae officer: Chief Operating Officer 675 S. SIERRA AVE,, UNIT 23, SOLANA BEACH CA 92075
Thomas Hallam director, officer: Chief Executive Officer C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Michael John Dawson officer: Chief Medical Officer C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
Yuma Regional Medical Center 10 percent owner 2400 S AVENUE A, YUMA AZ 85364
Stephanie Diaz director C/O SENECA BIOPHARMA, INC., 20271 GOLDENROD LANE, GERMANTOWN MD 20876
James R Neal director 2910 SEVENTH STREET, BERKELEY CA 94710
Mary Ann Gray director 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
David J Mazzo director 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Binxian Wei director P.O. BOX 2231, LIVINGSTON NJ 07039
Kenneth C Carter director, officer: Executive Chairman 20358 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Cristina Csimma director 14 CAMBRIDGE CENTER, BLDG 1, CAMBRIDGE MA 02142

Palisade Bio (Palisade Bio) Headlines

From GuruFocus

Palisade Bio Regains Compliance with Nasdaq Listing Requirements

By Value_Insider Value_Insider 12-01-2022